You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel approach to restricting the spread of neurofibrillary tau

    SBC: NOVORON BIOSCIENCE INC            Topic: NIA

    7. Project Summary Alzheimer’s disease (AD) is the most common cause of dementia and is a growing problem as populations age. More than 25 million people are affected by dementia worldwide with most suffering from AD. AD is characterized by the presence of plaques of insoluble amyloid-beta (Aβ) and tangles of hyperphosphorylated aggregates of the cytoskeletal protein, tau. Thus far, most AD tre ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Triagonist Peptide Therapeutics for Neuroprotection

    SBC: VELUM INC            Topic: 300

    Project Summary Morbidity associated with neuronal degeneration and dysfunction poses an increasing public health burden. Among the wide range of etiologies that result in neuronal dysfunction, including chronic conditions such as Alzheimer’s and Parkinson’s disease and vascular dementias, one major cause that has been largely unnoticed but is increasingly recognized as a major concern is trau ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery

    SBC: MERCATOR MEDSYSTEMS, INC.            Topic: NHLBI

    PROJECT SUMMARY Post-thrombotic syndrome (PTS) is a chronic debilitating condition characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. It occurs within 2 years of deep vein thrombosis (DVT) treatment in 50-60% of patients with iliofemoral thrombosis and in 30-50% of all DVT patients regardless of thrombosis location (1). Even with pharmacolo ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Ultrahigh Throughput Microscale Mass Spectrometry for Pharmaceutical Prenylation Enzyme Engineering

    SBC: Fluid Discovery Inc            Topic: 400

    Project Summary Biocatalyst can be key tools in the synthesis of natural product-based pharmaceuticals and as powerful components of the pharmaceutical chemist’s drug modification kit. For example, the aromatic prenyltransferase NphB has utility in the synthesis of common prenylated compounds or derived backbones include cannabinoids, alpha acids, beta acids, phenylpropanoids, naphterpins, and m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Thermostable Inactivated Potent Yellow Fever Vaccine

    SBC: UNIVERSAL STABILIZATION TECHNOLOGIES, INC.            Topic: NIAID

    SummaryYellow Fever (YF) is an acute viral hemorrhagic fever disease caused by Yellow Fevervirus (YFV) and an estimated 200,000 YF infections occur annually. Approximately 50% ofinfected individuals that develop a severe case of the disease will die. The infection iscommon in Africa and South America, and travelers and residents of those areas are athigh risk of contracting the virus. A recent res ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Diagnosis of Esophageal Squamous Cell Carcinoma in Low-Income Countries

    SBC: CAPSULOMICS INC            Topic: 102

    Esophageal squamous cell carcinoma (ESCC) causes more than 509,000 deaths per year worldwide, and over 80% of these cases occur in low- and middle-income countries (LMICs). In the settings where it is available and affordable, ESCC diagnosis is made using the highly invasive and expensive procedure known as esophagogastroduodenoscopy (EGD, also referred to as upper endoscopy). However, citizens of ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media

    SBC: OSSIUM HEALTH INC            Topic: 400

    ABSTRACT:The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the Cost of Goods (COGs). This is because, the current cell culture methods require frequent and complete media replacement in order to remove toxic metabolites from culture. This practice of co ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. A novel approach to Mesenchymal Stem Cell Transduction

    SBC: OSSIUM HEALTH INC            Topic: NHLBI

    PROJECT SUMMARY Mesenchymal stem cells (MSC) are in clinical development for cardiovascular, neurologic, orthopedic, and other indications. Ossium is developing a novel source of MSC from vertebral bodies (vbMSC). Genetic modification of vbMSC using lentiviral vector (LV) has the potential to improve the therapeutic potential. Understanding how genetic modification might alter the vbMSC phenotype ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Bronchoscopic lung navigation system for accurately excising lung nodules

    SBC: Navigation Sciences, Inc.            Topic: 102

    ABSTRACT The long-term goal of this project is to develop and commercialize a navigation system that can accurately determine margins in real-time during surgery for lung cancer. Surgery is currently the standard of care for early stage lung cancer. A critical challenge is to reliably identify small, early-stage tumors and resect them with sufficient margins (distance between the edge of tumor and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Engineering a long-acting relaxin agonist to treat liver fibrosis

    SBC: ZEBRA BIOLOGICS INC            Topic: 300

    Project Summary/AbstractRelaxin is a heterodimeric 53 amino acid peptide hormone that induces cardiovascular compliance and reproductive tissue remodeling during pregnancy and parturition. In addition to reproductive organs, the relaxin receptor, RXFP1, is also expressed in the liver, heart, lung, kidney, bone and skin. This broad tissue localization has led to the recognition that relaxin is a pl ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government